Andere Sprachen Chiome Bioscience Inc.

Aktien

A1JTP0

JP3205350006

4583

Markt geschlossen - Japan Exchange Andere Börsenplätze 08:00:00 31.05.2024			% 5 Tage	% 1. Jan.
119 ^JPY	+3.48%		+4.39%	-11.85%

13.02.	Chiome Bioscience Inc. kündigt Betrauungsvertrag mit Takeda Pharmaceutical Company Limited an	CI
13.02.	Chiome Bioscience Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Chiome Bioscience Inc. Announces Entrustment Agreement with Takeda Pharmaceutical Company Limited	13.02.
Chiome Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13.02.
Chiome Bioscience Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	14.11.
Chiome Bioscience Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	09.08.23
Chiome Bioscience Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11.05.23
Chiome Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	14.02.23
Chiome Bioscience Inc. Provided Sales Guidance for 2023	14.02.23
Chiome Bioscience Inc. Announces Termination of the License Agreement for Anti-TROP-2 Antibody Development and Commercialization with Shanghai Henlius Biotech, Inc	17.01.23
Chiome Bioscience Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022	14.11.22
Heidelberg Pharma Enters Research Collaboration Deal With Japan's Chiome Bioscience	13.07.22
Chiome Bioscience Inc. Announces Conclusion of Target-Specific Research and Option Agreement with Heidelberg Pharma	13.07.22
Japan Index Snaps Three-day Winning Streak on Inflationary Pressures; Kudan Shares Expand 7%	12.07.22
Chiome Bioscience Inc. Announces Service Agreement with Option Contract with Rohto Pharmaceutical Co., Ltd	11.07.22
Chiome Bioscience Inc. Announces First Patient in of Cancer Therapeutic Antibody CBA-1535 in A Phase 1 Clinical Trial	04.07.22
Chiome Bioscience Inc. Announces Conclusion of Contract with Additional Institutes and First Dosing of CBA-1205 in the Second Part of Phase 1 Study	13.06.22
Japan Index Trims Gains over Inflationary Pressures; Dena to Take Majority Stake in Mobile ICT Business for $230 Million	27.05.22
Chiome Bioscience Inc. Submits an Initial Application for Phase I Study on CBA-1535	16.02.22
Chiome Bioscience Inc. and Fujirebio, Inc. Enter into License Agreement	15.02.22
Chiome Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	14.02.22
Chiome Bioscience Inc. Announces Move to the Second Half Part of Phase 1 Clinical Trial of First-In-Class CBA-1205	24.12.21

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Chiome Bioscience Inc.

Aktien

A1JTP0

JP3205350006

4583

Andere Sprachen

Filter